Generalized Pustular Psoriasis (GPP) Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Generalized Pustular Psoriasis (GPP).
Found 1 Approved Drug for Generalized Pustular Psoriasis (GPP)
Spevigo
Generic Name
Spesolimab-Sbzo
Spevigo
Generic Name
Spesolimab-Sbzo
Form: Injection
Method of administration: Intravenous
FDA approval date: September 01, 2022
Classification: Interleukin-36 Receptor Antagonist
SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances